MOVE logo

MOVE (MOVE)

Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

MOVE steht fuer MOVE, ein Healthcare-Unternehmen mit einem Kurs von $14.79 (Marktkapitalisierung 12M). Die Aktie erzielt 54/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.

Zuletzt analysiert: 5. Feb. 2026
54/100 KI-Bewertung MCap 12M Vol 44K

MOVE (MOVE) Gesundheitswesen & Pipeline-Uebersicht

CEOJohn Mastrototaro
Mitarbeiter32
HauptsitzPleasanton, CA, US
IPO-Jahr2021

Movano Inc. is pioneering wearable health solutions with its Movano Ring, leveraging innovative radiofrequency technology for comprehensive health monitoring and women-centric design, positioning it at the forefront of personalized preventative healthcare and setting the stage for expansion into continuous glucose monitoring and cuffless blood pressure measurement.

Datenherkunft | Finanzdaten Quantitative Analyse NASDAQ Analyse: 5. Feb. 2026

Investmentthese

Investing in Movano Inc. presents a high-risk, high-reward opportunity. The company's focus on wearable health technology, particularly the Movano Ring, addresses a growing market for personalized health monitoring. Successful commercialization of the Movano Ring, coupled with the development of non-invasive glucose monitoring and cuffless blood pressure measurement, could drive significant revenue growth. The investment thesis hinges on the company's ability to secure regulatory approvals, demonstrate clinical validity, and effectively market its products. However, the company's negative profit margin of -3409.6% and gross margin of -270.2% highlight the financial challenges. Investors may want to evaluate the potential for substantial returns against the backdrop of significant financial risks and intense competition. The company's market capitalization of $0.01 billion reflects its early stage and associated risks.

Basierend auf FMP-Finanzdaten und quantitativer Analyse

Wichtige Highlights

  • Market capitalization of $0.01 billion indicates the company's small size and potential for high growth but also signifies higher risk.
  • P/E ratio of -62.51 reflects the company's current lack of profitability.
  • Profit margin of -3409.6% highlights significant financial challenges and the need for substantial revenue growth.
  • Gross margin of -270.2% indicates that the cost of goods sold exceeds revenue, necessitating improvements in operational efficiency and pricing strategies.
  • Beta of 0.82 suggests that the stock is less volatile than the overall market.

Wettbewerber & Vergleichsunternehmen

Staerken

  • Innovative radiofrequency sensor technology.
  • Focus on women's health.
  • Potential for non-invasive monitoring solutions.
  • Comprehensive health data integration.

Schwaechen

  • Negative profitability and gross margins.
  • Limited financial resources.
  • Small market capitalization.
  • Reliance on successful product development and regulatory approvals.

Katalysatoren

  • Upcoming: Regulatory approvals for the Movano Ring and its features.
  • Upcoming: Successful completion of clinical trials for non-invasive glucose monitoring.
  • Upcoming: Strategic partnerships with healthcare providers and insurance companies.
  • Ongoing: Continued development and refinement of the Movano platform.
  • Ongoing: Increasing consumer awareness and adoption of wearable health technology.

Risiken

  • Potential: Failure to obtain regulatory approvals for new products and features.
  • Potential: Unsuccessful clinical trials for non-invasive monitoring technologies.
  • Ongoing: Intense competition from larger, more established companies.
  • Ongoing: Limited financial resources and potential need for additional funding.
  • Ongoing: Risk of technological obsolescence and the need for continuous innovation.

Wachstumschancen

  • Commercialization of the Movano Ring: The successful launch and market adoption of the Movano Ring represent a significant growth opportunity. The ring's comprehensive health monitoring capabilities, coupled with its women-centric design, could attract a substantial customer base. The wearable health tech market is projected to reach $30 billion by 2028, providing a large addressable market for Movano. The timeline for widespread adoption depends on regulatory approvals and effective marketing strategies. A key competitive advantage lies in the ring's unique radiofrequency-based sensor technology.
  • Expansion into Continuous Glucose Monitoring (CGM): The development of non-invasive CGM capabilities presents a substantial growth opportunity. The global CGM market is expected to reach $10 billion by 2027, driven by the increasing prevalence of diabetes and the demand for convenient monitoring solutions. Movano's non-invasive approach could differentiate it from existing CGM technologies that require skin punctures. The timeline for commercialization depends on successful clinical trials and regulatory clearance. A competitive advantage could be the integration of CGM data with the Movano Ring's existing health metrics.
  • Development of Cuffless Blood Pressure Monitoring: Integrating cuffless blood pressure monitoring into the Movano platform offers another significant growth avenue. The market for blood pressure monitoring devices is substantial, with a growing demand for convenient and accurate solutions. Movano's cuffless technology could provide a more user-friendly alternative to traditional blood pressure cuffs. The timeline for commercialization depends on achieving clinical accuracy and regulatory approval. A competitive advantage lies in the potential for continuous and unobtrusive blood pressure monitoring.
  • Strategic Partnerships and Collaborations: Forming strategic partnerships with healthcare providers, insurance companies, and technology firms could accelerate market penetration and expand Movano's reach. Collaborations with healthcare providers could facilitate clinical validation and adoption of Movano's products. Partnerships with insurance companies could drive reimbursement and increase affordability for consumers. Collaborations with technology firms could enhance the platform's capabilities and integration with other health and wellness ecosystems. The timeline for establishing these partnerships depends on successful product development and market traction.
  • Geographic Expansion: Expanding into new geographic markets represents a long-term growth opportunity. The global market for wearable health technology is growing rapidly, with significant potential in emerging economies. Adapting the Movano Ring and its associated services to meet the specific needs and preferences of different regions could drive international growth. The timeline for geographic expansion depends on securing regulatory approvals and establishing distribution channels in new markets. A key consideration is tailoring the product and marketing strategies to resonate with local cultures and healthcare systems.

Chancen

  • Growing market for wearable health technology.
  • Increasing demand for non-invasive monitoring solutions.
  • Potential for strategic partnerships and collaborations.
  • Expansion into new geographic markets.

Risiken

  • Intense competition from established medical device companies.
  • Regulatory hurdles and clinical trial risks.
  • Technological obsolescence.
  • Economic downturns affecting consumer spending.

Wettbewerbsvorteile

  • Proprietary radiofrequency sensor technology.
  • Focus on women-centric design and features.
  • Integration of multiple health monitoring capabilities into a single device.
  • Potential for non-invasive glucose and blood pressure monitoring.

Ueber MOVE

Movano Inc., founded in 2018 and based in Pleasanton, California, is a healthcare company focused on developing a platform that converges medical technology and consumer devices. Originally named Maestro Sensors Inc., the company rebranded to Movano Inc. to reflect its innovative approach to healthcare solutions. Movano's core technology revolves around radiofrequency (RF) technology, which enables the creation of miniaturized sensors suitable for wearable devices and other small form factors. Their primary product is the Movano Ring, a wearable device designed to monitor various health metrics, including heart rate, heart rate variability, sleep patterns, respiration rate, temperature, blood oxygen saturation, and activity levels such as steps and calories burned. The Movano Ring also incorporates features and design elements specifically tailored for women's health. Beyond the Movano Ring, the company is actively developing non-invasive continuous glucose monitoring (CGM) and cuffless blood pressure monitoring capabilities to further enhance its technology platform. These advancements aim to provide users with comprehensive and convenient health insights, positioning Movano as a key player in the evolving landscape of preventative and personalized healthcare.

Was das Unternehmen tut

  • Develop wearable medical devices.
  • Utilize radiofrequency technology for health monitoring.
  • Manufacture the Movano Ring for comprehensive health metrics tracking.
  • Focus on women-centric design and features.
  • Develop non-invasive continuous glucose monitoring (CGM) technology.
  • Develop cuffless blood pressure monitoring technology.
  • Integrate health data into a unified platform.

Geschaeftsmodell

  • Direct sales of the Movano Ring to consumers.
  • Potential subscription-based services for data analytics and personalized insights.
  • Partnerships with healthcare providers for remote patient monitoring.
  • Licensing of radiofrequency sensor technology.

Branchenkontext

Movano Inc. operates within the rapidly expanding medical device sector, specifically targeting the wearable health technology market. This market is driven by increasing consumer interest in personal health monitoring and preventative care. The competitive landscape includes established medical device companies and emerging technology firms. Key trends include the development of non-invasive monitoring technologies and the integration of AI for personalized health insights. Movano's success depends on its ability to differentiate its products through technological innovation, user-friendly design, and clinical validation. Competitors include ACON Laboratories, American Medical ID, Biolargo Inc., Bioxcel Therapeutics Inc., and G Medical Innovations Holdings Ltd.

Wichtige Kunden

  • Health-conscious individuals seeking proactive health monitoring.
  • Women interested in health tracking tailored to their needs.
  • Individuals with diabetes or at risk of developing diabetes.
  • Individuals with hypertension or at risk of developing hypertension.
KI-Zuversicht: 70% Aktualisiert: 5. Feb. 2026

Finanzdaten

Chart & Info

MOVE (MOVE) Aktienkurs: $14.79 (+0.44, +3.07%)

Aktuelle Nachrichten

Analystenkonsens

Konsens-Bewertung

Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer MOVE.

Kursziele

Wall-Street-Kurszielanalyse fuer MOVE.

MoonshotScore

54/100

Was bedeutet diese Bewertung?

Der MoonshotScore bewertet das Wachstumspotenzial von MOVE auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.

Was Anleger ueber MOVE (MOVE) wissen wollen

What are the key factors to evaluate for MOVE?

MOVE (MOVE) currently holds an AI score of 54/100, indicating moderate score. Key strength: Innovative radiofrequency sensor technology.. Primary risk to monitor: Potential: Failure to obtain regulatory approvals for new products and features.. This is not financial advice.

How frequently does MOVE data refresh on this page?

MOVE prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven MOVE's recent stock price performance?

Recent price movement in MOVE (MOVE) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative radiofrequency sensor technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider MOVE overvalued or undervalued right now?

Determining whether MOVE (MOVE) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying MOVE?

Before investing in MOVE (MOVE), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding MOVE to a portfolio?

Potential reasons to consider MOVE (MOVE) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Innovative radiofrequency sensor technology.. Additionally: Focus on women's health.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.

Can I buy fractional shares of MOVE?

Yes, most major brokerages offer fractional shares of MOVE (MOVE) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.

How can I track MOVE's earnings and financial reports?

MOVE (MOVE) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for MOVE earnings announcements is recommended.

Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.

Offizielle Ressourcen

Analyse aktualisiert am KI-Bewertung taeglich aktualisiert
Datenquellen & Methodik
Marktdaten bereitgestellt von Financial Modeling Prep & Yahoo Finance. KI-Analyse durch proprietaere Algorithmen von Stock Expert AI. Technische Indikatoren nach branchenueblichen Berechnungsstandards. Zuletzt aktualisiert: .

Daten dienen ausschliesslich zu Informationszwecken.

Analysehinweise
  • Information is based on available data and may be subject to change.
  • Financial metrics are as of the latest available data and may not reflect current performance.
  • Investment decisions should be based on individual risk tolerance and due diligence.
Datenquellen

Popular Stocks